MTOR and lymphangioleiomyomatosis: Patients with well-defined conditions stemming from mTOR overactivation, such as tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM), present more suitable study subjects due to their targeted treatment needs and longer life expectancy.